<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-59675</identifier>
<setSpec>0001-7310</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Adalimumab: the molecule and manufacturing procedure</dc:title>
<dc:description xml:lang="en">Adalimumab is a fully human monoclonal antibody targeted toward tumor necrosis factor alpha (TNF-&amp;#945;). El TNF-&amp;#945; is proinflammatory cytokine envolved in the patogenesis of many inflammatory diseases, as the psoriasis. The production process of adalimumab is complex and it is based in the called phague display technology (AU)</dc:description>
<dc:creator>Díaz-Pérez, J. L</dc:creator>
<dc:creator>Pérez-Barrio, S</dc:creator>
<dc:creator>Martínez de Lagrán, Z</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Adalimumab es un anticuerpo monoclonal totalmente humano y dirigido contra el factor de necrosis tumoral alfa (TNF-&amp;#945;). El TNF-&amp;#945; es una citocina proinflamatoria, implicada en la Etiopatogenia de múltiples entidades, entre ellas la psoriasis. El mecanismo de obtención de adalimumab es complejo y se basa en la denominada técnica de selección mediante presentación en fagos (AU)</dc:description>
<dc:source>Actas Dermosifiliogr;99(supl.3): 3-9, feb. 2008. ilus</dc:source>
<dc:identifier>ibc-59675</dc:identifier>
<dc:title xml:lang="es">Adalimumab: la molécula y el proceso de obtención</dc:title>
<dc:subject>^d1458^s22021</dc:subject>
<dc:subject>^d920^s29165</dc:subject>
<dc:subject>^d1458^s22044</dc:subject>
<dc:subject>^d920^s22079</dc:subject>
<dc:subject>^d920^s22002</dc:subject>
<dc:subject>^d920^s22078</dc:subject>
<dc:subject>^d920^s22044</dc:subject>
<dc:subject>^d28320^s22066</dc:subject>
<dc:subject>^d920^s22073</dc:subject>
<dc:subject>^d28320^s22045</dc:subject>
<dc:subject>^d12002^s22057</dc:subject>
<dc:type>article</dc:type>
<dc:date>200802</dc:date>
</metadata>
</record>
</ibecs-document>
